Pre-Surgery cocktail aims to boost liver cancer outcomes
NCT ID NCT07684040
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether giving a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted drug (rivoceranib) before surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination first, then undergo surgery if eligible. The main goal is to see how long it takes for the treatment to stop working, with secondary goals including survival and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebrelimab plus rivoceranib combined with hepatic arterial infusion chemotherapy
- What this could lead to
- If successful, this approach could improve the chances of successful liver cancer surgery and delay recurrence.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with no control group, so results may not be conclusive. The combination therapy carries risks of side effects from chemotherapy and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, 524000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?